Genfit Sa Share Price Today
(NASDAQ: GNFT)

Name: Genfit Sa Share Price Today (NASDAQ: GNFT) - Genfit Sa Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Genfit Sa share price is $3.7 & ₹321.79 as on 6 Mar 2025, 2.30 'hrs' IST

$3.7

▲

0.23

(6.63%)

Market is closed - opens 8 PM, 06 Mar 2025

View live Genfit Sa share price in Dollar and Rupees. Guide to invest in Genfit Sa stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Genfit Sa, along with analyst recommendations, forecasts, and comprehensive financials.

Genfit Sa share price movements

Today's Low: $3.62
Today's High: $3.70
$3.70
2.16%
Downside
Day's Volatility :2.16%
Upside
0.0%
52 Weeks Low: $3.35
52 Weeks High: $6.42
$3.70
9.46%
Downside
52 Weeks Volatility :47.84%
Upside
42.39%

Genfit Sa (GNFT) Returns

Period	Genfit Sa	Index (Russel 2000)
3 Months	-11.59%	0.0%
6 Months	-17.18%	0.0%
1 Year	-2.02%	0.0%
3 Years	10.51%	-11.6%

Genfit Sa (GNFT) Key Statistics

in dollars & INR

Previous Close	$3.47
Open	$3.62
Today's High	$3.7
Today's Low	$3.62
Market Capitalization	$177.7M
Today's Volume	$840.0
52 Week High	$6.4229
52 Week Low	$3.35
Revenue TTM	$80.5M
EBITDA	$21.9M
Earnings Per Share (EPS)	$0.39
PE Ratio	8.72
Profit Margin	27.68%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	25.91%

How to invest in Genfit Sa Stock (GNFT) from India?

It is very easy for Indian residents to invest directly in Genfit Sa from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Genfit Sa stock in both Indian Rupees (INR) and US Dollars (USD). Search for Genfit Sa or GNFT on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Genfit Sa or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Genfit Sa shares which would translate to 0.235 fractional shares of Genfit Sa as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Genfit Sa, in just a few clicks!

Returns in Genfit Sa (GNFT) for Indian investors in Rupees

The Genfit Sa stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Genfit Sa investment value today

Current value as on today

₹1,09,483

Returns

₹9,483

(+9.48%)

Returns from Genfit Sa Stock

₹4,520 (+4.52%)

Dollar Returns

₹4,963 (+4.96%)

Indian investors sentiment towards Genfit Sa (GNFT)

-36%

Period: Feb 3, 2025 to Mar 5, 2025. Change in 30 Days versus previous period

Search interest for Genfit Sa Stock from India on INDmoney has decreased by -36% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Genfit Sa

Millennium Management LLC
0.33%
Morgan Stanley - Brokerage Accounts
0.07%
UBS Group AG
0.01%

Analyst Recommendation on Genfit Sa

Buy

92%Buy

7%Hold

0%Sell

Based on 13 Wall street analysts offering stock ratings for Genfit Sa(by analysts ranked 0 to 5 stars)

Based on 13 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Genfit Sa Stock (GNFT)

What analysts predicted

Upside of 187.22%

Target:

$10.63

Current:

$3.70

Insights on Genfit Sa Stock (Ticker Symbol: GNFT)

Price Movement
In the last 6 months, GNFT stock has moved down by -17.2%
Increasing Revenue
Revenue is up for the last 4 quarters, 2.81M → 61.10M (in $), with an average increase of 59.2% per quarter
Increasing Net Profit
Netprofit is up for the last 3 quarters, -8.03M → 30.31M (in $), with an average increase of 101.5% per quarter
GNFT vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 62.3% return, outperforming this stock by 64.6%
GNFT vs VRTX (3 yr)
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 47.7% return, outperforming this stock by 46.5%
Price to Sales
ForGNFT every $1 of sales, investors are willing to pay $2.1, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $13.8 for every $1 of sales.

GNFT Genfit Sa Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$69.0K	↓ 41.53%
Net Income	$-79.5M	↑ 35.69%
Net Profit Margin	-115.2K%	↓ 65583.42%

	FY19	Y/Y Change
Revenue	$30.8M	↑ 44594.2%
Net Income	$-65.1M	↓ 18.08%
Net Profit Margin	-211.24%	↑ 115036.59%

	FY20	Y/Y Change
Revenue	$765.0K	↓ 97.52%
Net Income	$-101.2M	↑ 55.38%
Net Profit Margin	-13.2K%	↓ 13020.26%

	FY21	Y/Y Change
Revenue	$80.1M	↑ 10366.54%
Net Income	$67.3M	↓ 166.45%
Net Profit Margin	84.0%	↑ 13315.5%

	FY22	Y/Y Change
Revenue	$20.2M	↓ 74.78%
Net Income	$-23.7M	↓ 135.27%
Net Profit Margin	-117.45%	↓ 201.45%

	FY23	Y/Y Change
Revenue	$28.6M	↑ 41.45%
Net Income	$-28.9M	↑ 21.81%
Net Profit Margin	-101.15%	↑ 16.3%

	Q1 FY23	Q/Q Change
Revenue	$7.6M	↑ 23.97%
Net Income	$-10.4M	-
Net Profit Margin	-138.0%	-

	Q2 FY23	Q/Q Change
Revenue	$11.5M	↑ 51.96%
Net Income	$-20.9M	↑ 100.0%
Net Profit Margin	-181.62%	↓ 43.62%

	Q3 FY23	Q/Q Change
Revenue	$2.8M	↓ 75.46%
Net Income	$-4.0M	↓ 80.72%
Net Profit Margin	-142.65%	↑ 38.97%

	Q4 FY23	Q/Q Change
Revenue	$17.1M	↑ 506.21%
Net Income	$-8.0M	↑ 100.0%
Net Profit Margin	-47.06%	↑ 95.59%

	Q1 FY24	Q/Q Change
Revenue	$30.6M	↑ 78.84%
Net Income	$15.2M	↓ 288.5%
Net Profit Margin	49.61%	↑ 96.67%

	Q2 FY24	Q/Q Change
Revenue	$61.1M	↑ 100.0%
Net Income	$30.3M	↑ 100.0%
Net Profit Margin	49.61%	↑ 0.0%

	FY18	Y/Y Change
Profit	$-1.8M	↓ 15.44%

	FY19	Y/Y Change
Profit	$30.8M	↓ 1827.68%

	FY20	Y/Y Change
Profit	$563.0K	↓ 98.17%

	FY21	Y/Y Change
Profit	$79.9M	↑ 14093.25%

	FY22	Y/Y Change
Profit	$19.9M	↓ 75.04%

	FY23	Y/Y Change
Profit	$28.2M	↑ 41.49%

	Q1 FY23	Q/Q Change
Profit	$7.6M	-

	Q2 FY23	Q/Q Change
Profit	$15.1M	↑ 100.0%

	Q3 FY23	Q/Q Change
Profit	$2.8M	↓ 81.35%

	Q4 FY23	Q/Q Change
Profit	$17.1M	↑ 506.21%

	Q1 FY24	Q/Q Change
Profit	$30.6M	↑ 78.84%

	Q2 FY24	Q/Q Change
Profit	$60.2M	↑ 97.18%

	FY18	Y/Y Change
Operating Cash Flow	$-56.1M	↑ 12.49%
Investing Cash Flow	$-4.0M	↑ 35.21%
Financing Cash Flow	$-6.5M	↓ 103.74%

	FY19	Y/Y Change
Operating Cash Flow	$-47.7M	↓ 14.98%
Investing Cash Flow	$327.0K	↓ 108.2%
Financing Cash Flow	$116.9M	↓ 1893.98%

	FY20	Y/Y Change
Operating Cash Flow	$-96.4M	↑ 102.12%
Investing Cash Flow	$-966.0K	↓ 395.41%
Financing Cash Flow	$-8.3M	↓ 107.06%

	FY21	Y/Y Change
Operating Cash Flow	$99.9M	↓ 203.68%
Investing Cash Flow	$-3.4M	↑ 249.59%
Financing Cash Flow	$-8.9M	↑ 7.99%

	Q1 FY23	Q/Q Change
Operating Cash Flow	$-12.5M	↓ 52.04%
Investing Cash Flow	$1.3M	↑ 0.0%
Financing Cash Flow	$-882.0K	↑ 5.0%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-25.8M	↑ 106.13%
Investing Cash Flow	$1.3M	↑ 0.0%
Financing Cash Flow	$-995.0K	↑ 12.81%

Genfit Sa Technicals Summary

Sell

Neutral

Buy

Genfit Sa is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Genfit Sa (GNFT) Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Genfit Sa	-7.22%	-17.18%	-2.02%	10.51%	-76.25%
Regeneron Pharmaceuticals, Inc.	1.3%	-41.29%	-30.51%	9.2%	42.38%
Beone Medicines Ltd	15.19%	34.31%	61.3%	43.16%	68.1%
Vertex Pharmaceuticals Incorporated	3.37%	3.77%	18.06%	106.43%	121.36%
Alnylam Pharmaceuticals, Inc.	-11.52%	-3.4%	62.32%	49.04%	120.93%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Genfit Sa	8.72	8.72	NA	0.58	0.26	0.07	NA	1.96
Regeneron Pharmaceuticals, Inc.	17.85	17.85	1.03	43.09	0.16	0.07	0.01	273.57
Beone Medicines Ltd	NA	NA	NA	1.43	-0.19	-0.06	NA	31.22
Vertex Pharmaceuticals Incorporated	32.84	NA	1.33	18.07	-0.03	0.13	NA	63.87
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	0.57	-15.01	-0.03	NA	0.52

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Genfit Sa	Buy	$177.7M	-76.25%	8.72	27.68%
Regeneron Pharmaceuticals, Inc.	Buy	$74.9B	42.38%	17.85	31.07%
Beone Medicines Ltd	NA	$28.5B	68.1%	NA	-16.92%
Vertex Pharmaceuticals Incorporated	Buy	$124.1B	121.36%	32.84	-4.86%
Alnylam Pharmaceuticals, Inc.	Buy	$31.5B	120.93%	NA	-12.37%

About Genfit Sa

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.

Organization	Genfit Sa
Employees	169
CEO	Mr. M. Pascal Prigent
Industry	Biotechnology

Management People of Genfit Sa

Name	Title
Mr. Jean-Francois Mouney	Co-Founder & Chairman of the Board
Mr. M. Pascal Prigent	Chief Executive Officer
Prof. Bart Staels	Co-Founder & Chairman of the Scientific Advisory Board
Mr. Thomas Baetz	Chief Financial Officer
Mr. Pascal Caisey	Chief Operating Officer
Dr. Meriam Kabbaj Ph.D.	Chief Technology Officer
Dr. Dean W. Hum Ph.D.	Chief Scientific Officer
Mr. Jean-Christophe Marcoux	Chief Corporate Affairs Officer, Head of Investor Relations & Head of ESG
Mr. Laurent Lannoo	Corporate Secretary & Director of Legal Affairs
Ms. Stefanie Magner J.D.	Chief Compliance Officer & Executive VP of International Legal Affairs

Important FAQs about investing in GNFT Stock from India :

What is Genfit Sa share price today?

Genfit Sa share price today stands at $3.70, Open: $3.62 ; Previous Close: $3.47 ; High: $3.70 ; Low: $3.62 ; 52 Week High: $6.42 ; 52 Week Low: $3.35.

The stock opens at $3.62, after a previous close of $3.47. The stock reached a daily high of $3.70 and a low of $3.62, with a 52-week high of $6.42 and a 52-week low of $3.35.

Can Indians buy Genfit Sa shares?

Yes, Indians can invest in the Genfit Sa (GNFT) from India.

With INDmoney, you can buy Genfit Sa at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Genfit Sa at zero transaction cost.

How can I buy Genfit Sa shares from India?

It is very easy to buy Genfit Sa from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Genfit Sa (GNFT) be purchased?

Yes, you can buy fractional shares of Genfit Sa with INDmoney app.

What are the documents required to start investing in Genfit Sa stocks?

To start investing in Genfit Sa, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.